Syncom Formulations India
BSE: 524470 | NSE: SYNCOMF | ISIN: INE312C01025 | SECTOR: Biotechnology & DrugsOpen
13.99High
13.99Low
13.60Prev Close
13.78P/E
-Median P/E
-P/B
-Median P/B
-Market Cap
13.02BVolume
458.99KVol. (20 day Avg.)
0PEG
-Div.Yield
-Bid
13.84Ask
-
Company Description
- Biotechnology & Drugs
BSE
524470NSE
SYNCOMFISIN
INE312C01025
Syncom Formulations (India) Limited is an India-based company that is engaged in the pharmaceutical business. The Company is engaged in the manufacturing and dealing in pharmaceutical drugs and formulations, and trading of commodities. It is also engaged in the renting of properties. It manufactures and markets a range of pharmaceutical formulations in various dosage forms, such as tablets, capsules, liquids orals, liquid vials and ampoule injections and dry powder injections, ophthalmic preparations, dry syrups and suspensions, ointments, creams, gel, ORS and jelly. The Company's domestic division product categories include Cratus Life Care, Cratus Evolve and Cratus Right Nutrition. Its products include Ciprofloxacin Tablets USP 250 mg, Ciprofloxacin Tablets USP 500 mg, Ciprofloxacin Tablets USP 750 mg, Cefazolin For Injection USP 1 gm, Cefotaxime For Injection USP 1 gm, Ceftriaxone for Injection USP 500 mg, Cefuroxime For Injection USP 750 mg and Gentamicin Injection BP 40 mg.
Company Officers
Kedarmal Bankda
Executive Chairman of the BoardAnkit Bankda
Chief Financial OfficerVaishali Agrawal
Compliance Officer, Company SecretaryVijay Bankda
Managing Director, Executive DirectorRinki Bankda
Whole-Time Director